Gene · 8453
CUL2: cullin 2
12 sourcesgene-search-2026-11-11-0.2.0
Download JSON
Cite this record
ConductScience Library. CUL2: cullin 2. Genes, record 8453. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/8453
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q13617 | Cullin-2 | 745 | 42 | Ensembl, GeneID, HGNC |
Source UniProt
Patents51
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4650780 A2 | 2025-11-19 | 9516 | Q13617 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 9763 | Q13617 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 9763 | Q13617 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 9516 | Q13617 | Espacenet |
| JP 2024123008 A | 2024-09-10 | 5694 | Q13617 | Espacenet |
| JP 2024123008 A | 2024-09-10 | 5695 | Q13617 | Espacenet |
| JP 2024123008 A | 2024-09-10 | 5696 | Q13617 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 20772 | Q13617 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 20773 | Q13617 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 20774 | Q13617 | Espacenet |
1 to 10 of 51
See all 51 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,371
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | CUL2 papers | Newest fiscal year |
|---|---|---|---|
| P30CA021765 | Cancer Center Support Grant (CCSG) | 18 | 2025 |
| R01AG011085 | Ubiquitin‐mediated proteolysis and cell cycle control | 18 | 2025 |
| ZIABC011028 | Clinical Studies of the Molecular Genetic Basis of Kidney Cancer | 12 | 2025 |
| ZIABC011038 | Molecular Therapeutics of Kidney Cancer: VHL Gene and Fumarate Hydratase Gene | 12 | 2025 |
| ZIABC011043 | Molecular Therapeutics of Kidney Cancer: MET Gene and BHD Gene | 11 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 10 | 2025 |
| R35CA197589 | Inducing Proximity: An Emerging Paradigm for New Therapeutic Modalities | 10 | 2025 |
| ZIDBC011089 | Clinical Nursing and Data Management Core | 9 | 2025 |
| P30CA046592 | University of Michigan Rogel Cancer Center Support Grant 2023-2028 | 7 | 2025 |
| P30AI027763 | UCSF-Bay Area Center for AIDS Research | 6 | 2025 |
1 to 10 of 1,371Source NIH's project files
See all 1,371 nih grantsPapers2,064
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Performance of Rilpivirine-Based Hydrophobic Tags and PROTACs Directed Against HIV-1 Reverse Transcriptase. | bioRxiv | 2026 | 42818120 | PubTator, text mining | PubMed |
| Degrading GPX4 via Biomimetic Nanoparticle-Mediated In Situ Synthesis of Deep-Learning-Designed Binder-Degron Chimeras for Prostate Cancer Therapy. | Adv Sci (Weinh) | 2026 | 42801636 | PubTator, text mining | PubMed |
| Beyond hypoxia and ccRCC: the expanding universe of VHL novel targets and next-generation therapeutics. | Biomark Res | 2026 | 42717364 | PubTator, text mining | PubMed |
| PRAME promotes invasion and metastasis of salivary adenoid cystic carcinoma by regulating RARα stability via the cullin2 ubiquitin-proteasome system. | Clin Transl Med | 2026 | 42660821 | PubTator, text mining | PubMed |
| Recent advances in etiology and treatment of von Hippel-Lindau Disease (VHLD). | Cancer Metastasis Rev | 2026 | 42593521 | PubTator, text mining | PubMed |
| Alphavirus M1 disrupts super-enhancer-driven oncogenic transcription via non-structural protein NSP2 in osteosarcoma. | Nat Commun | 2026 | 42386745 | PubTator, text mining | PubMed |
| A microprotein encoded by FERMT3 modulates endothelial cell protein catabolism and induces cell cycle arrest and senescence. | Cell Commun Signal | 2026 | 42343301 | PubTator, text mining | PubMed |
| Structure of the E3 ligase CRL2ZYG11B with substrates reveals the molecular basis for N-degron recognition and ubiquitination. | Cell Rep | 2026 | 42224082 | PubTator, text mining | PubMed |
| Cysteine availability tunes ubiquitin signaling via inverse stability of LRRC58 E3 ligase and its substrate CDO1. | Nat Commun | 2026 | 42098103 | PubTator, text mining | PubMed |
| Interface Architecture of a VHL-PROTAC Complex with and without Cullin-2. | J Am Chem Soc | 2026 | 42089481 | PubTator, text mining | PubMed |
1 to 10 of 2,064
See all 2,064 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/8453
GET https://conductscience.org/api/genes/v1/8453/patents?page=2